January 7, 2025 02:29 PM ESTUpdated 02:59 PM
FDA+

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Zachary Brennan

Senior Editor

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said Tues­day, tak­ing the rare step of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

With schiz­o­phre­nia tri­al suc­cess, LB Phar­ma­ceu­ti­cals thinks about Phase 3 and next fund­ing

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Jasper re­ports more da­ta in spon­ta­neous hives from tiny study

A service from the Financial Times